|
FR901228A
(fr)
|
1943-01-16 |
1945-07-20 |
Deutsche Edelstahlwerke Ag |
Système d'aimant à entrefer annulaire
|
|
ZA737247B
(en)
|
1972-09-29 |
1975-04-30 |
Ayerst Mckenna & Harrison |
Rapamycin and process of preparation
|
|
DE3381783D1
(de)
|
1982-03-03 |
1990-09-13 |
Genentech Inc |
Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
|
|
US5906936A
(en)
|
1988-05-04 |
1999-05-25 |
Yeda Research And Development Co. Ltd. |
Endowing lymphocytes with antibody specificity
|
|
AU4308689A
(en)
|
1988-09-02 |
1990-04-02 |
Protein Engineering Corporation |
Generation and selection of recombinant varied binding proteins
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
EP0585287B1
(en)
|
1990-07-10 |
1999-10-13 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
DE69129154T2
(de)
|
1990-12-03 |
1998-08-20 |
Genentech, Inc., South San Francisco, Calif. |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
DK0517895T3
(da)
|
1990-12-14 |
1997-04-07 |
Univ California |
Kimæriske kæder til receptorforbundne signaltransduktionsveje
|
|
ES2330052T3
(es)
|
1991-03-01 |
2009-12-03 |
Dyax Corporation |
Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas.
|
|
IL101147A
(en)
|
1991-03-07 |
2004-06-20 |
Gen Hospital Corp |
Redirection of cellular immunity by receptor chimeras
|
|
US6004811A
(en)
|
1991-03-07 |
1999-12-21 |
The Massachussetts General Hospital |
Redirection of cellular immunity by protein tyrosine kinase chimeras
|
|
US7049136B2
(en)
|
1991-03-07 |
2006-05-23 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
|
ATE414768T1
(de)
|
1991-04-10 |
2008-12-15 |
Scripps Research Inst |
Bibliotheken heterodimerer rezeptoren mittels phagemiden
|
|
US5199942A
(en)
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
|
DE4122599C2
(de)
|
1991-07-08 |
1993-11-11 |
Deutsches Krebsforsch |
Phagemid zum Screenen von Antikörpern
|
|
GB9125768D0
(en)
|
1991-12-04 |
1992-02-05 |
Hale Geoffrey |
Therapeutic method
|
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
DK1621554T4
(da)
|
1992-08-21 |
2012-12-17 |
Univ Bruxelles |
Immunoglobuliner blottet for lette kæder
|
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
|
US7211259B1
(en)
|
1993-05-07 |
2007-05-01 |
Immunex Corporation |
4-1BB polypeptides and DNA encoding 4-1BB polypeptides
|
|
WO1995014023A1
(en)
|
1993-11-19 |
1995-05-26 |
Abbott Laboratories |
Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
|
|
HUT74686A
(en)
|
1993-12-17 |
1997-01-28 |
Sandoz Ag |
Rapamycin derivatives, their pharmaceutical use, process for producing them and pharmaceutical composition containing them as active agents
|
|
US5362718A
(en)
|
1994-04-18 |
1994-11-08 |
American Home Products Corporation |
Rapamycin hydroxyesters
|
|
AU694222B2
(en)
|
1994-05-02 |
1998-07-16 |
Bernd Groner |
Bifunctional protein, preparation and use
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US5786464C1
(en)
|
1994-09-19 |
2012-04-24 |
Gen Hospital Corp |
Overexpression of mammalian and viral proteins
|
|
US5712149A
(en)
|
1995-02-03 |
1998-01-27 |
Cell Genesys, Inc. |
Chimeric receptor molecules for delivery of co-stimulatory signals
|
|
US6103521A
(en)
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
|
PT871495E
(pt)
|
1995-02-24 |
2005-10-31 |
Gen Hospital Corp |
Redireccionamento de imunidade celular atraves de receptores quimericos
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
AU2466895A
(en)
|
1995-04-28 |
1996-11-18 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
ES2187660T3
(es)
|
1995-06-09 |
2003-06-16 |
Novartis Ag |
Derivados de rapamicina.
|
|
BE1009856A5
(fr)
|
1995-07-14 |
1997-10-07 |
Sandoz Sa |
Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
|
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
|
US5874240A
(en)
|
1996-03-15 |
1999-02-23 |
Human Genome Sciences, Inc. |
Human 4-1BB receptor splicing variant
|
|
EP0937082A2
(en)
|
1996-07-12 |
1999-08-25 |
Ariad Pharmaceuticals, Inc. |
Materials and method for treating or preventing pathogenic fungal infection
|
|
DE69738749D1
(de)
|
1996-08-16 |
2008-07-17 |
Schering Corp |
Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
|
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
|
US6114148C1
(en)
|
1996-09-20 |
2012-05-01 |
Gen Hospital Corp |
High level expression of proteins
|
|
JP2002512502A
(ja)
|
1996-10-25 |
2002-04-23 |
セル・ジェネシス・インコーポレイテッド |
癌細胞の標的細胞溶解
|
|
JP4215172B2
(ja)
|
1996-12-03 |
2009-01-28 |
アムジェン フレモント インク． |
複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
|
|
US6258558B1
(en)
|
1997-01-21 |
2001-07-10 |
The General Hospital Corporation |
Method for selection of proteins using RNA-protein fusions
|
|
JP3614866B2
(ja)
|
1997-06-12 |
2005-01-26 |
リサーチ コーポレイション テクノロジーズ，インコーポレイティド |
人工抗体ポリペプチド
|
|
US20030060444A1
(en)
|
1997-06-25 |
2003-03-27 |
Celltech Therapeutics, Ltd. |
Cell activation process and reagents therefor
|
|
GB9713473D0
(en)
|
1997-06-25 |
1997-09-03 |
Celltech Therapeutics Ltd |
Biological products
|
|
US6015815A
(en)
|
1997-09-26 |
2000-01-18 |
Abbott Laboratories |
Tetrazole-containing rapamycin analogs with shortened half-lives
|
|
TW557297B
(en)
|
1997-09-26 |
2003-10-11 |
Abbott Lab |
Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
|
|
CA2308114A1
(en)
|
1997-10-21 |
1999-04-29 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
|
|
IL137409A0
(en)
|
1998-02-09 |
2001-07-24 |
Genentech Inc |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
|
JP4843138B2
(ja)
|
1998-04-15 |
2011-12-21 |
ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド |
Ｔ細胞阻害性受容体組成物およびその使用
|
|
GB9809658D0
(en)
|
1998-05-06 |
1998-07-01 |
Celltech Therapeutics Ltd |
Biological products
|
|
EP1109921A4
(en)
|
1998-09-04 |
2002-08-28 |
Sloan Kettering Inst Cancer |
FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF
|
|
AU2472400A
(en)
|
1998-10-20 |
2000-05-08 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
|
WO2000063374A1
(en)
|
1999-04-16 |
2000-10-26 |
Celltech Therapeutics Limited |
Synthetic transmembrane components
|
|
IL147442A0
(en)
|
1999-07-12 |
2002-08-14 |
Genentech Inc |
Promotion or inhibition of angiogenesis and cardiovscularization by tumor necrosis factor ligand/receptor homologs
|
|
EP1212331B1
(en)
|
1999-08-24 |
2004-04-21 |
Ariad Gene Therapeutics, Inc. |
28-epirapalogs
|
|
EP1235842A4
(en)
|
1999-10-15 |
2003-04-23 |
Univ Massachusetts |
Rna interference pathway genes as tools for targeted genetic interference
|
|
GB9925848D0
(en)
|
1999-11-01 |
1999-12-29 |
Celltech Therapeutics Ltd |
Biological products
|
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
|
ATE373078T1
(de)
|
2000-02-24 |
2007-09-15 |
Xcyte Therapies Inc |
Gleichzeitige stimulation und konzentration von zellen
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
IL136511A0
(en)
|
2000-06-01 |
2001-06-14 |
Gavish Galilee Bio Appl Ltd |
Genetically engineered mhc molecules
|
|
WO2001096584A2
(en)
|
2000-06-12 |
2001-12-20 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
|
GB0025307D0
(en)
|
2000-10-16 |
2000-11-29 |
Celltech Chiroscience Ltd |
Biological products
|
|
US7229960B2
(en)
*
|
2000-11-03 |
2007-06-12 |
University Of Vermont And State Agricultural College |
Methods and compositions for inhibiting GRB7
|
|
EP1334188B1
(en)
|
2000-11-07 |
2006-08-30 |
City of Hope |
Cd19-specific redirected immune cells
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
CN1294148C
(zh)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
环状单链三特异抗体
|
|
WO2002088334A1
(en)
|
2001-04-30 |
2002-11-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
US7514537B2
(en)
|
2001-04-30 |
2009-04-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human gliomas
|
|
EP2281837B1
(en)
|
2001-08-10 |
2016-10-05 |
Aberdeen University |
Antigen binding domains from fish
|
|
JP4578098B2
(ja)
|
2001-10-01 |
2010-11-10 |
ダイアックス、コープ |
多重鎖真核ディスプレイベクターとその使用
|
|
US20030148982A1
(en)
|
2001-11-13 |
2003-08-07 |
Brenner Malcolm K. |
Bi-spcific chimeric T cells
|
|
WO2003057171A2
(en)
|
2002-01-03 |
2003-07-17 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US7638326B2
(en)
|
2002-01-03 |
2009-12-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform
|
|
JP4547911B2
(ja)
|
2002-02-01 |
2010-09-22 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
リン含有化合物およびその用途
|
|
GB0208104D0
(en)
|
2002-04-09 |
2002-05-22 |
Univ Dundee |
Method
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
US20040047858A1
(en)
|
2002-09-11 |
2004-03-11 |
Blumberg Richard S. |
Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
|
|
CN1753912B
(zh)
|
2002-12-23 |
2011-11-02 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
|
KR20060052681A
(ko)
|
2003-05-23 |
2006-05-19 |
와이어쓰 |
Ｇｉｔｒ 리간드, ｇｉｔｒ 리간드-연관 분자, 항체 및그의 용도
|
|
AU2004255216B2
(en)
|
2003-07-01 |
2010-08-19 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
|
EP1660126A1
(en)
|
2003-07-11 |
2006-05-31 |
Schering Corporation |
Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
|
|
US8198020B2
(en)
|
2003-08-22 |
2012-06-12 |
Potentia Pharmaceuticals, Inc. |
Compositions and methods for enhancing phagocytosis or phagocyte activity
|
|
US20050113564A1
(en)
|
2003-11-05 |
2005-05-26 |
St. Jude Children's Research Hospital |
Chimeric receptors with 4-1BB stimulatory signaling domain
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
US7220755B2
(en)
|
2003-11-12 |
2007-05-22 |
Biosensors International Group, Ltd. |
42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
|
|
JP2007518399A
(ja)
|
2003-12-02 |
2007-07-12 |
ジェンザイム コーポレイション |
肺癌を診断および治療する組成物並びに方法
|
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
|
AU2005250408B2
(en)
|
2004-05-27 |
2010-09-23 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
EP1765402A2
(en)
|
2004-06-04 |
2007-03-28 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
|
WO2006020258A2
(en)
|
2004-07-17 |
2006-02-23 |
Imclone Systems Incorporated |
Novel tetravalent bispecific antibody
|
|
US7994298B2
(en)
|
2004-09-24 |
2011-08-09 |
Trustees Of Dartmouth College |
Chimeric NK receptor and methods for treating cancer
|
|
WO2006060878A1
(en)
|
2004-12-10 |
2006-06-15 |
Peter Maccallum Cancer Institute |
Methods and compositions for adoptive immunotherapy
|
|
PT2343320T
(pt)
|
2005-03-25 |
2018-01-23 |
Gitr Inc |
Anticorpos anti-gitr e as suas utilizações
|
|
MX2007013978A
(es)
|
2005-05-09 |
2008-02-22 |
Ono Pharmaceutical Co |
Anticuerpos monoclonales humanos a muerte programada 1 (pd-1) y metodos para tratamiento de cancer utilizando anticuerpos anti-pd-1 solos o en combinacion con otros inmunoterapeuticos.
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
CN105330741B
(zh)
|
2005-07-01 |
2023-01-31 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
US20070036773A1
(en)
|
2005-08-09 |
2007-02-15 |
City Of Hope |
Generation and application of universal T cells for B-ALL
|
|
NZ612578A
(en)
|
2005-08-19 |
2014-11-28 |
Abbvie Inc |
Dual variable domain immunoglobin and uses thereof
|
|
NZ594630A
(en)
|
2005-10-07 |
2013-04-26 |
Exelixis Inc |
N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
|
|
US20110212086A1
(en)
|
2006-01-19 |
2011-09-01 |
Genzyme Corporation |
GITR Antibodies For The Treatment of Cancer
|
|
WO2008045437A2
(en)
|
2006-10-09 |
2008-04-17 |
The General Hospital Corporation |
Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
|
|
US20080131415A1
(en)
|
2006-11-30 |
2008-06-05 |
Riddell Stanley R |
Adoptive transfer of cd8 + t cell clones derived from central memory cells
|
|
PT2856876T
(pt)
|
2007-03-30 |
2018-03-28 |
Memorial Sloan Kettering Cancer Center |
Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos
|
|
KR101562580B1
(ko)
|
2007-06-18 |
2015-10-22 |
머크 샤프 앤 도메 비.브이. |
사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
|
|
DK2175884T3
(en)
|
2007-07-12 |
2016-09-26 |
Gitr Inc |
Combination USING GITR BINDING MOLECULES
|
|
US8359965B2
(en)
|
2007-09-17 |
2013-01-29 |
Oxford J Craig |
Apparatus and method for broad spectrum radiation attenuation
|
|
CA2700860C
(en)
|
2007-10-01 |
2016-07-19 |
Jonathan A. Terrett |
Human antibodies that bind mesothelin, and uses thereof
|
|
CA2703947C
(en)
|
2007-10-26 |
2018-12-04 |
Governing Council Of The University Of Toronto |
Therapeutic and diagnostic methods using tim-3
|
|
WO2009097140A1
(en)
|
2008-01-30 |
2009-08-06 |
Memorial Sloan-Kettering Cancer Center |
Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors
|
|
ES2639857T3
(es)
|
2008-02-11 |
2017-10-30 |
Cure Tech Ltd. |
Anticuerpos monoclonales para el tratamiento del tumor
|
|
AU2009215375A1
(en)
|
2008-02-21 |
2009-08-27 |
Astrazeneca Ab |
Combination therapy 238
|
|
US8379824B2
(en)
|
2008-03-06 |
2013-02-19 |
At&T Intellectual Property I, Lp |
Methods and apparatus to provide a network-based caller identification service in a voice over internet protocol network
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
EP2310508A1
(en)
|
2008-07-02 |
2011-04-20 |
Emergent Product Development Seattle, LLC |
Tgf-b antagonist multi-target binding proteins
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
NZ591130A
(en)
|
2008-08-25 |
2012-09-28 |
Amplimmune Inc |
Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
|
|
WO2010027827A2
(en)
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Targeted costimulatory polypeptides and methods of use to treat cancer
|
|
EP4032552B1
(en)
|
2008-08-26 |
2023-10-04 |
City of Hope |
Method and compositions for enhanced anti-tumor effector functioning of t cells
|
|
JPWO2010030002A1
(ja)
|
2008-09-12 |
2012-02-02 |
国立大学法人三重大学 |
外来性ｇｉｔｒリガンド発現細胞
|
|
US8476431B2
(en)
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
|
BRPI0917592B1
(pt)
|
2008-12-09 |
2021-08-17 |
Genentech, Inc |
Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição
|
|
WO2010085660A2
(en)
|
2009-01-23 |
2010-07-29 |
Roger Williams Hospital |
Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
|
|
US8741295B2
(en)
|
2009-02-09 |
2014-06-03 |
Universite De La Mediterranee |
PD-1 antibodies and PD-L1 antibodies and uses thereof
|
|
EA201190132A1
(ru)
|
2009-02-23 |
2013-01-30 |
Гленмарк Фармасьютикалс С.А. |
Гуманизированные антитела, связывающиеся с cd19, и их применение
|
|
CA2756393C
(en)
*
|
2009-03-24 |
2017-06-20 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Anti-mesothelin antibodies
|
|
WO2010114484A1
(en)
|
2009-04-03 |
2010-10-07 |
S*Bio Pte Ltd |
Pyrimidine substituted purine compounds as kinase (s) inhibitors
|
|
HRP20151099T8
(en)
|
2009-04-30 |
2016-01-29 |
Tel Hashomer Medical Research |
Anti ceacam1 antibodies and methods of using same
|
|
RU2595409C2
(ru)
|
2009-09-03 |
2016-08-27 |
Мерк Шарп И Доум Корп., |
Анти-gitr-антитела
|
|
AU2010301042B2
(en)
|
2009-10-01 |
2014-03-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
US20130017199A1
(en)
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
|
JP5856073B2
(ja)
|
2009-12-29 |
2016-02-09 |
エマージェント プロダクト デベロップメント シアトル， エルエルシー |
Ｒｏｎ結合構築体およびその使用方法
|
|
CN102134276A
(zh)
*
|
2010-01-22 |
2011-07-27 |
上海抗体药物国家工程研究中心有限公司 |
一种抗ctla-4嵌合抗体
|
|
WO2011097477A1
(en)
|
2010-02-04 |
2011-08-11 |
The Trustees Of The University Of Pennsylvania |
Icos critically regulates the expansion and function of inflammatory human th17 cells
|
|
JP2013532153A
(ja)
|
2010-06-18 |
2013-08-15 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
|
|
TW201244719A
(en)
|
2010-07-09 |
2012-11-16 |
Exelixis Inc |
Combinations of kinase inhibitors for the treatment of cancer
|
|
KR20130043198A
(ko)
|
2010-07-16 |
2013-04-29 |
피라말 엔터프라이지즈 리미티드 |
키나제 억제제로서 치환된 이미다조퀴놀린 유도체
|
|
WO2012012667A2
(en)
|
2010-07-21 |
2012-01-26 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of a hla locus
|
|
NZ609967A
(en)
|
2010-10-27 |
2015-04-24 |
Baylor College Medicine |
Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
US9233125B2
(en)
|
2010-12-14 |
2016-01-12 |
University Of Maryland, Baltimore |
Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
|
|
AU2011349443B2
(en)
|
2010-12-20 |
2015-12-24 |
Genentech, Inc. |
Anti-mesothelin antibodies and immunoconjugates
|
|
CA3179835A1
(en)
|
2011-01-18 |
2012-07-26 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating cancer
|
|
CN110200997A
(zh)
|
2011-03-23 |
2019-09-06 |
弗雷德哈钦森癌症研究中心 |
用于细胞免疫治疗的方法和组合物
|
|
WO2012127464A2
(en)
|
2011-03-23 |
2012-09-27 |
Gavish-Galilee Bio Applications Ltd |
Constitutively activated t cells for use in adoptive cell therapy
|
|
SG193956A1
(en)
|
2011-04-01 |
2013-11-29 |
Sloan Kettering Inst Cancer |
T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
|
|
US9266960B2
(en)
|
2011-04-08 |
2016-02-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
|
|
JP6066991B2
(ja)
|
2011-04-08 |
2017-01-25 |
ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ |
キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法
|
|
US20130071414A1
(en)
|
2011-04-27 |
2013-03-21 |
Gianpietro Dotti |
Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
|
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
EP4488370A2
(en)
|
2011-07-25 |
2025-01-08 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expresssion of dux4
|
|
CN104114233B
(zh)
*
|
2011-07-29 |
2021-11-12 |
宾夕法尼亚大学董事会 |
转换共刺激受体
|
|
BR112014003214A2
(pt)
|
2011-08-11 |
2017-03-14 |
Intellikine Llc |
polimorfos inibidores de cinase
|
|
US9833476B2
(en)
|
2011-08-31 |
2017-12-05 |
The Trustees Of Dartmouth College |
NKP30 receptor targeted therapeutics
|
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
|
WO2013040577A1
(en)
|
2011-09-16 |
2013-03-21 |
The Research Foundation Of State University Of New York |
Aptamers resistant to nucleocapsid degradation
|
|
BR112014006176A8
(pt)
|
2011-09-16 |
2017-09-12 |
Univ Pennsylvania |
Rna transcrito in vitro ou rna sintético, composição, método para gerar uma população de células t geneticamente modificadas por rna, e, uso de uma célula t geneticamente modificada
|
|
WO2013040371A2
(en)
|
2011-09-16 |
2013-03-21 |
Baylor College Of Medicine |
Targeting the tumor microenvironment using manipulated nkt cells
|
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
|
CN103946242A
(zh)
|
2011-10-20 |
2014-07-23 |
美国卫生和人力服务部 |
抗cd22嵌合抗原受体
|
|
WO2013063419A2
(en)
*
|
2011-10-28 |
2013-05-02 |
The Trustees Of The University Of Pennsylvania |
A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
|
WO2013074916A1
(en)
*
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
|
WO2013082366A1
(en)
|
2011-12-01 |
2013-06-06 |
The Brigham And Women's Hospital, Inc. |
Anti-ceacam1 recombinant antibodies for cancer therapy
|
|
EP2817331B1
(en)
*
|
2012-02-22 |
2023-08-30 |
The Trustees of the University of Pennsylvania |
Use of the cd2 signaling domain in second-generation chimeric antigen receptors
|
|
WO2013126726A1
(en)
*
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Double transgenic t cells comprising a car and a tcr and their methods of use
|
|
CN104159909A
(zh)
|
2012-02-22 |
2014-11-19 |
宾夕法尼亚大学董事会 |
产生用于癌症治疗的t细胞持续性群体的组合物和方法
|
|
WO2013126720A2
(en)
*
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing
|
|
EA201491574A1
(ru)
|
2012-02-22 |
2014-12-30 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Применение car, основанных на icos, для усиления противоопухолевой активности и длительного сохранения car
|
|
CA3116051C
(en)
*
|
2012-03-23 |
2023-09-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
|
RS59199B1
(sr)
|
2012-05-25 |
2019-10-31 |
Univ California |
Metode i jedinjenja za rnk-upravljanu ciljanu dnk modifikaciju i za rnk- upravljanu modulaciju transkripta
|
|
KR20210149195A
(ko)
|
2012-07-13 |
2021-12-08 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
형질도입된 ｔ 세포의 투여 적합성을 평가하는 방법
|
|
MX2015000426A
(es)
|
2012-07-13 |
2015-07-14 |
Univ Pennsylvania |
Incremento de actividad de celulas t car mediante cointroduccion de un anticuerpo biespecifico.
|
|
IN2015DN00139A
(Direct)
|
2012-07-13 |
2015-06-12 |
Univ Pennsylvania |
|
|
JP6382191B2
(ja)
|
2012-07-13 |
2018-08-29 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
Ｃａｒの抗腫瘍活性のための毒性管理
|
|
US20160235787A1
(en)
|
2012-07-13 |
2016-08-18 |
The Trustees Of The University Of Pennsylvania |
Epitope Spreading Associated with CAR T-Cells
|
|
CN104507537A
(zh)
|
2012-07-13 |
2015-04-08 |
宾夕法尼亚大学董事会 |
用于调节car t细胞的组合物和方法
|
|
CA2916638C
(en)
|
2012-07-31 |
2021-01-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
|
CN102775500A
(zh)
|
2012-08-03 |
2012-11-14 |
郑骏年 |
嵌合抗原受体iRGD-scFv(G250)-CD8-CD28-CD137-CD3ζ及其用途
|
|
SI2884999T2
(sl)
|
2012-08-20 |
2026-01-30 |
Fred Hutchinson Cancer Center |
Metoda in sestavki za celično imunoterapijo
|
|
WO2014039513A2
(en)
|
2012-09-04 |
2014-03-13 |
The Trustees Of The University Of Pennsylvania |
Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
|
|
EP2900695B1
(en)
|
2012-09-27 |
2018-01-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antibodies and methods for eliciting potent antitumor activity
|
|
CN102875685B
(zh)
*
|
2012-09-29 |
2013-12-25 |
郑骏年 |
嵌合抗原受体hFⅦL-CD8-OX40-CD3ζ及其用途
|
|
EP2904106A4
(en)
|
2012-10-01 |
2016-05-11 |
Univ Pennsylvania |
COMPOSITIONS AND METHOD FOR TARGETING CURRIC ACIDS FOR THE TREATMENT OF CANCER
|
|
US10117896B2
(en)
|
2012-10-05 |
2018-11-06 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
CN104853776B
(zh)
|
2012-10-12 |
2021-04-09 |
布里格姆及妇女医院股份有限公司 |
免疫应答的增强
|
|
EP3825401A1
(en)
|
2012-12-12 |
2021-05-26 |
The Broad Institute, Inc. |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
IL300461A
(en)
|
2012-12-12 |
2023-04-01 |
Harvard College |
Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
|
|
CN103145849B
(zh)
*
|
2013-02-18 |
2014-06-11 |
冯振卿 |
嵌合抗原受体及其用途
|
|
HUE046961T2
(hu)
|
2013-02-20 |
2020-04-28 |
Univ Pennsylvania |
Rák kezelése humanizált EGFRVIII elleni kiméra antigénreceptor alkalmazásával
|
|
TW201446794A
(zh)
|
2013-02-20 |
2014-12-16 |
Novartis Ag |
利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向
|
|
EP2970426B1
(en)
|
2013-03-15 |
2019-08-28 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
BR112016013187A2
(pt)
|
2013-12-19 |
2017-09-26 |
Novartis Ag |
receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos
|
|
US10287354B2
(en)
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
EP3097117B1
(en)
|
2014-01-21 |
2023-10-04 |
Novartis Ag |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
|
US20170081411A1
(en)
|
2014-03-15 |
2017-03-23 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
MX395149B
(es)
|
2014-04-07 |
2025-03-24 |
Novartis Ag |
Terapias de combinación que comprenden un receptor quimérico de antígeno cd19 para el cáncer.
|
|
MX2017001011A
(es)
|
2014-07-21 |
2018-05-28 |
Novartis Ag |
Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
|
|
US9777061B2
(en)
|
2014-07-21 |
2017-10-03 |
Novartis Ag |
Treatment of cancer using a CD33 chimeric antigen receptor
|
|
AR101829A1
(es)
|
2014-07-21 |
2017-01-18 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1
|
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
US20170226495A1
(en)
|
2014-07-21 |
2017-08-10 |
Novartis Ag |
Sortase molecules and uses thereof
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
US20170274014A1
(en)
|
2014-07-21 |
2017-09-28 |
Jennifer Brogdon |
Combinations of low, immune enhancing, doses of mtor inhibitors and cars
|
|
US20170209492A1
(en)
|
2014-07-31 |
2017-07-27 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
JP6919118B2
(ja)
|
2014-08-14 |
2021-08-18 |
ノバルティス アーゲー |
ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
|
|
TW202140557A
(zh)
|
2014-08-19 |
2021-11-01 |
瑞士商諾華公司 |
使用cd123嵌合抗原受體治療癌症
|
|
KR20210149228A
(ko)
|
2014-09-17 |
2021-12-08 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
|
CA2963935A1
(en)
|
2014-10-08 |
2016-04-14 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
|
US20170239294A1
(en)
|
2014-10-15 |
2017-08-24 |
Novartis Ag |
Compositions and methods for treating b-lymphoid malignancies
|
|
US20180334490A1
(en)
*
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
EP4036109A3
(en)
|
2014-12-29 |
2022-10-12 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2016115482A1
(en)
*
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
|
WO2016126608A1
(en)
*
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
WO2016164580A1
(en)
|
2015-04-07 |
2016-10-13 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
|
CN119925616A
(zh)
|
2015-04-08 |
2025-05-06 |
诺华股份有限公司 |
Cd20疗法、cd22疗法和与cd19嵌合抗原受体（car）表达细胞的联合疗法
|
|
CA2982996A1
(en)
|
2015-04-17 |
2016-10-20 |
David Maxwell Barrett |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
TWI859112B
(zh)
*
|
2015-07-21 |
2024-10-21 |
瑞士商諾華公司 |
改良免疫細胞之功效及擴展之方法
|
|
WO2017027392A1
(en)
|
2015-08-07 |
2017-02-16 |
Novartis Ag |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
CN108780084B
(zh)
|
2015-09-03 |
2022-07-22 |
诺华股份有限公司 |
预测细胞因子释放综合征的生物标志物
|
|
IL297003A
(en)
|
2015-09-17 |
2022-12-01 |
Novartis Ag |
car-t cell treatments with improved efficacy
|
|
EP3393504B1
(en)
|
2015-12-22 |
2025-09-24 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
EP3397756B1
(en)
|
2015-12-30 |
2023-03-08 |
Novartis AG |
Immune effector cell therapies with enhanced efficacy
|
|
CN110225927B
(zh)
|
2016-10-07 |
2024-01-12 |
诺华股份有限公司 |
用于治疗癌症的嵌合抗原受体
|
|
CN109134660B
(zh)
*
|
2017-06-16 |
2022-07-01 |
上海恒润达生生物科技股份有限公司 |
靶向Mesothelin的嵌合抗原受体并联合表达抗PD1抗体的方法及其用途
|
|
EP3746116A1
(en)
*
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Combination therapy using a chimeric antigen receptor
|
|
JP7313642B2
(ja)
*
|
2020-08-06 |
2023-07-25 |
ジャスミー株式会社 |
端末装置、情報処理システム及びプログラム
|